EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study

Zhaoguo Lin, Wenzhu Hu, Mengting Li, Zhidi Pan, Yuan Feng, Xiao Zhang, Biao Yang, Yongkang Gai, Dawei Jiang, Jianwei Zhu, Xiong Cai, Xiaoli Lan

European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3891-3903

DOI: 10.1007/s00259-025-07739-5 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.02.2026. Verfasst von Zhaoguo Lin und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, H…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Glypicans, Liver Neoplasms, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Science and Technology Program of Hubei Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Accurate diagnosis of hepatocellular carcinoma (HCC) remains a clinical challenge. Glypican-3 (GPC3) is highly expressed in HCC but not in normal liver tissue, making it a promising target for PET-based molecular imaging, which may complement existing approaches for HCC diagnosis. In this study, we developed a new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and conducted a first-in-human, proof-of-concept evaluation in patients with HCC to assess its clinical feasibility. METHODS: An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (68Ga) to obtain [68Ga]Ga-aGPC3-Fab. In vitro assays, small-animal PET/CT scans, and ex vivo biodistribution experiments were conducted to examine its GPC3 targeting ability. Five patients with radiologically suspected or diagnosed HCC were enrolled in a pilot clinical study and underwent [68Ga]Ga-aGPC3-Fab PET imaging. Radiotracer uptake in tumor and non-tumor tissues was quantitatively analyzed. RESULTS: [68Ga]Ga-aGPC3-Fab was synthesized with high radiochemical purity and demonstrated strong affinity and efficient internalization in GPC3-positive cells. It enabled clear tumor visualization in both subcutaneous and orthotopic GPC3-positive HCC mouse models. All five patients tolerated the PET procedure well, with no adverse effects. [68Ga]Ga-aGPC3-Fab successfully detected intrahepatic metastases approximately 1 cm in diameter with high imaging contrast, including lesions that missed on magnetic resonance imaging. CONCLUSION: [68Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularGlypicansLiver NeoplasmsPositron Emission Tomography Computed TomographyAgedAnimalsFemaleHumansMaleMiceMiddle AgedCell Line, TumorGallium RadioisotopesTissue DistributionTranslational Research, Biomedical

Stichwörter der Autor:innen

Antigen-binding fragmentGlypican-3Hepatocellular carcinomaImmuno-positron emission tomographyNuclear medicine

Substanzen

Gallium RadioisotopesGallium-68GlypicansGPC3 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Ave, Wuhan, Hubei Province, 430022, China.
  • Hubei Key Laboratory of Molecular Imaging, No. 1277 Jiefang Ave, Wuhan, Hubei Province, 430022, China.
  • Key Laboratory of Biological Targeted Therapy, The Ministry of Education, No. 1277 Jiefang Ave, Wuhan, Hubei Province, 430022, China.
  • Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai, 200240, China.
  • Jecho Institute, Shanghai, 200240, China.
  • Jecho Laboratories, Inc., Frederick, MD, 21704, USA.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Science and Technology Program of Hubei Province
  • Hubei Science and Technology Innovation Talent Program
  • Natural Science Foundation of Hubei Province
  • Innovative Drug Research and Development-National Science and Technology Major Project

Zitieren

APA

Lin, Z., Hu, W., Li, M., Pan, Z., Feng, Y., Zhang, X., Yang, B., Gai, Y., Jiang, D., Zhu, J., Cai, X., & Lan, X. (2026). Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3891-3903. https://doi.org/10.1007/s00259-025-07739-5

Vancouver

Lin Z, Hu W, Li M, Pan Z, Feng Y, Zhang X, et al. Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3891-3903. doi:10.1007/s00259-025-07739-5

BibTeX
@article{Lin2026,
  author = {Lin, Zhaoguo and Hu, Wenzhu and Li, Mengting and Pan, Zhidi and Feng, Yuan and Zhang, Xiao and Yang, Biao and Gai, Yongkang and Jiang, Dawei and Zhu, Jianwei and Cai, Xiong and Lan, Xiaoli},
  title = {Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {3891--3903},
  doi = {10.1007/s00259-025-07739-5}
}
Kostenlos starten →